Von Hippel-Lindau Management Medication Savings with TheDrugClub
Discount pricing may be available. Current formulary eligibility is being verified; a condition association does not establish FREE coverage.
- Join TheDrugClub for $19.95/month
- Receive your member card by email
- Present your card at a participating pharmacy
- Check active-formulary eligibility or available discount pricing
About Von Hippel-Lindau Management
Von Hippel-Lindau (VHL) is a rare, inherited genetic disorder characterized by the growth of tumors and cysts in various parts of the body. Managing VHL often requires specialized, ongoing care and can involve costly medications. TheDrugClub understands the significant financial impact this can have. Our membership program is designed to help individuals and families reduce their prescription costs, making vital treatments more accessible and affordable.
Von Hippel-Lindau (VHL) is a rare, inherited genetic disorder caused by a mutation in the VHL gene. This mutation leads to the abnormal growth of blood vessels, forming tumors known as hemangioblastomas, which can appear in the brain, spinal cord, and retina. VHL can also cause cysts and tumors in other organs, including the kidneys, pancreas, adrenal glands (pheochromocytomas), and inner ear. Because VHL can affect multiple organ systems and the severity can vary widely, regular monitoring and early intervention are crucial for managing the condition and preventing serious complications.
Understanding VHL Management and Treatments
Managing VHL typically involves a multidisciplinary approach, with treatment plans tailored to the individual's specific manifestations of the disease. Common treatments and interventions include:
- Regular Monitoring: Due to the potential for new tumor growth, individuals with VHL undergo frequent screenings, such as MRI and CT scans of the brain, spine, and abdomen, as well as ophthalmological exams and audiograms. Urine tests may also be used to check for pheochromocytomas.
- Surgery: This is often the primary treatment for symptomatic or growing tumors, especially those in the brain, spinal cord, or kidneys. The goal is to remove tumors while preserving organ function.
- Targeted Therapy: For certain VHL-associated tumors, like kidney tumors, central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors that don't require immediate surgery, medications like belzutifan (Welireg) may be prescribed. This targeted therapy works by blocking a pathway that promotes tumor growth.
- Radiation Therapy: In some cases, radiation therapy may be used for tumors that are difficult to
The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.